TAYSHA GENE THERAPIES INC
NASDAQ: TSHA (Taysha Gene Therapies, Inc.)
Kemas kini terakhir: 34 minit lalu6.67
-0.18 (-2.63%)
| Penutupan Terdahulu | 6.85 |
| Buka | 6.75 |
| Jumlah Dagangan | 3,277,204 |
| Purata Dagangan (3B) | 2,796,144 |
| Modal Pasaran | 1,916,698,112 |
| Harga / Jualan (P/S) | 314.29 |
| Harga / Buku (P/B) | 9.25 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 May 2026 |
| Margin Operasi (TTM) | -930.54% |
| EPS Cair (TTM) | -0.340 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -32.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 111.93% |
| Nisbah Semasa (MRQ) | 5.35 |
| Aliran Tunai Operasi (OCF TTM) | -83.45 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -52.28 M |
| Pulangan Atas Aset (ROA TTM) | -35.91% |
| Pulangan Atas Ekuiti (ROE TTM) | -159.34% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Taysha Gene Therapies, Inc. | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 3.5 |
| Osilator Teknikal | 4.0 |
| Purata | 0.50 |
|
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 12.11% |
| % Dimiliki oleh Institusi | 67.23% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Ra Capital Management, L.P. | 31 Dec 2025 | 23,555,648 |
| Avoro Capital Advisors Llc | 31 Dec 2025 | 21,700,000 |
| Rtw Investments, Lp | 31 Dec 2025 | 16,398,297 |
| Vestal Point Capital, Lp | 31 Dec 2025 | 13,750,000 |
| Siren, L.L.C. | 31 Dec 2025 | 10,129,913 |
| Octagon Capital Advisors Lp | 31 Dec 2025 | 8,859,911 |
| Polar Capital Holdings Plc | 31 Dec 2025 | 7,931,403 |
| Barclays Plc | 31 Dec 2025 | 5,539,001 |
| Julat 52 Minggu | ||
| Median | 10.00 (49.93%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Needham | 03 Mar 2026 | 10.00 (49.93%) | Beli | 4.53 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 06 Mar 2026 | CNBC | FDA reversals leave investors worrying about the fates of other experimental drugs |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |